ArticleJournal of human virology
Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus.
Article in Journal of human virology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 35 citations in OpenAlex.
- Nucleocapsid protein of SARS-CoV-2 is a potential target for developing new generation of vaccine.Journal of clinical laboratory analysis · 2022Article
- Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development.NPJ vaccines · 2018Review
- Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials.PLoS pathogens · 2013Review
- Advanced vaccine candidates for Lassa fever.Viruses · 2012Review
- Article
- Characterization of Lassa virus cell entry and neutralization with Lassa virus pseudoparticles.Journal of virology · 2009Article
- Reverse genetics approaches to combat pathogenic arenaviruses.Antiviral research · 2008Review
- Article
- Article
- Envelope exchange for the generation of live-attenuated arenavirus vaccines.PLoS pathogens · 2006Article
- A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses.Journal of virology · 2005Article
- LCMV-mediated hepatitis in rhesus macaques: WE but not ARM strain activates hepatocytes and induces liver regeneration.Archives of virology · 2004Article
- Mucosal arenavirus infection of primates can protect them from lethal hemorrhagic fever.Journal of medical virology · 2004Article
- Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virus.Journal of medical virology · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectivesLassa fever virus (LAS) is transmitted to man by rodent carriers and is fatal in a third of untreated cases. Our goal is to provide immune protection from Lassa fever by mucosal vaccination. STUDY DESIGN/
methodsMice were vaccinated intragastrically with control vectors or with vectors (vaccinia or Salmonella) expressing LAS nucleocapsid protein (NP). Mice were challenged intracranially with a lethal dose of the related arenavirus, lymphocytic choriomeningitis virus (LCMV), as a measure of the vaccine's ability to elicit cross-protection.
resultsSalmonella and vaccinia vectors expressing LAS NP each protected a third of the mice from lethal challenge with LCMV. All mice vaccinated with a vector expressing LCMV NP were protected as expected.
conclusionsThe LAS recombinant Salmonella vector is comparable to the LAS recombinant vaccinia vector in its ability to cross-protect mice from lethal challenge. Nucleocapsid protein is an inadequate immunogen on its own, but provides sufficient cross-protection to make it a useful component of a broadly reactive arenavirus vaccine.
Indexed as
Identifiers
11437313PMC2391007W182245619What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.